$9.13
-0.98-9.73%
Last update: Nov 12, 7:35 PM
Absci Corp
ABSINASDAQ
Absci rose 168.7% from $3.40 to $9.14, ahead of the S&P 500's +10.8%. Its worst day was Nov 13 (−22.4%), and its low came Mar 12 at $2.30.
Nov 12, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.20 beat the $-0.20 estimate on $378,000.00 revenue (est. $1.7M).
−22.4%, the year's worst day · S&P 500 −1.7%
Absci closed at its lowest level of the year, 32.4% below where the year started.
Story events cover the past 12 months · Times ET
−6.1% · S&P 500 −1.5%
EPS of $-0.20 missed the $-0.17 estimate on $650,000.00 revenue (est. $2.3M).
−3.0% · S&P 500 +0.6%
Absci shares rose 23.1%, while the S&P 500 rose 0.2%.
+23.1% · S&P 500 +0.2%
EPS of $-0.19 beat the $-0.20 estimate on $215,000.00 revenue (est. $1.6M).
+2.6% · S&P 500 +0.8%
Absci shares rose 23.6%, while the S&P 500 rose 0.4%.
+23.6% · S&P 500 +0.4%
Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month periodFirst multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic
+36.0%, the year's best day, on 38M shares, the year's heaviest volume · S&P 500 0.0%
EPS of $-0.21 missed the $-0.19 estimate on $318,000.00 revenue (est. $1.3M).
+1.0% · S&P 500 +0.3%
Absci closed at its highest level of the year, 255.9% above where the year started.
+1.9% · S&P 500 −0.4%
EPS of $-0.19 beat the $-0.19 estimate on $304,000.00 revenue (est. $991,360.00).
−9.7% · S&P 500 −0.4%
Where it ended: a close of $9.13 on Nov 12, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.19, revenue est. $991,360.00).
Nothing in the past 12 months.
All ABSI dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ABSI and SPY from Benzinga historical bars. Not investment advice.
